Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
18 June 2021Website:
http://codexdna.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
TBIO Latest News
Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery
Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.
Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].
What type of business is Telesis Bio?
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
What sector is Telesis Bio in?
Telesis Bio is in the Healthcare sector
What industry is Telesis Bio in?
Telesis Bio is in the Medical Devices industry
What country is Telesis Bio from?
Telesis Bio is headquartered in United States
When did Telesis Bio go public?
Telesis Bio initial public offering (IPO) was on 18 June 2021
What is Telesis Bio website?
https://codexdna.com
Is Telesis Bio in the S&P 500?
No, Telesis Bio is not included in the S&P 500 index
Is Telesis Bio in the NASDAQ 100?
No, Telesis Bio is not included in the NASDAQ 100 index
Is Telesis Bio in the Dow Jones?
No, Telesis Bio is not included in the Dow Jones index
When does Telesis Bio report earnings?
Next earnings report date is not announced yet